Focused On-demand Library for Cyclic nucleotide-gated cation channel beta-1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q14028

UPID:
CNGB1_HUMAN

ALTERNATIVE NAMES:
Cyclic nucleotide-gated cation channel 4; Cyclic nucleotide-gated cation channel gamma; Cyclic nucleotide-gated cation channel modulatory subunit; Cyclic nucleotide-gated channel beta-1; Glutamic acid-rich protein

ALTERNATIVE UPACC:
Q14028; H3BN09; O43636; Q13059; Q14029; Q9UMG2

BACKGROUND:
The protein Cyclic nucleotide-gated cation channel beta-1, with alternative names such as Cyclic nucleotide-gated channel beta-1 and Glutamic acid-rich protein, is integral to the function of CNG channels. These channels are essential for the transduction of visual and olfactory signals, regulating the flow of ions in response to light-induced cGMP level alterations. Its isoform, GARP2, plays a regulatory role in rod photoreceptor phosphodiesterase, essential for reducing 'dark noise' and facilitating the detection of single photons.

THERAPEUTIC SIGNIFICANCE:
Cyclic nucleotide-gated cation channel beta-1's involvement in Retinitis pigmentosa 45, a disease marked by progressive vision loss, underscores its potential as a target for therapeutic intervention. Exploring the mechanisms by which this protein influences retinal health and function could lead to breakthroughs in treating Retinitis pigmentosa and similar visual impairments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 159 of 8789